Novo Nordisk, Pfizer sweeten bid for Metsera as bidding war heats up

Core Insights - Novo Nordisk and Pfizer have revised their bids for Metsera, an obesity drug developer [1] Company Developments - Novo Nordisk and Pfizer are actively competing for Metsera, indicating a strategic interest in the obesity treatment market [1] Industry Trends - The revision of bids by major pharmaceutical companies highlights the growing focus on obesity drug development and the potential for significant market opportunities in this sector [1]